Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Alendronate and risedronate: reports of severe bone, joint, and muscle pain.

Literature DB >> 15710802

Alendronate and risedronate: reports of severe bone, joint, and muscle pain.

Diane K Wysowski, Jennie T Chang.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2005 PMID： 15710802 DOI： 10.1001/archinte.165.3.346-b

Source DB: PubMed Journal: Arch Intern Med ISSN： 0003-9926

Keyword Cloud
Cited

× No keyword cloud information.

29 in total

1. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.

Authors: Nelson B Watts; John P Bilezikian; Pauline M Camacho; Susan L Greenspan; Steven T Harris; Stephen F Hodgson; Michael Kleerekoper; Marjorie M Luckey; Michael R McClung; Rachel Pessah Pollack; Steven M Petak
Journal: Endocr Pract Date: 2010 Nov-Dec Impact factor: 3.443

2. Text mining for adverse drug events: the promise, challenges, and state of the art.

Authors: Rave Harpaz; Alison Callahan; Suzanne Tamang; Yen Low; David Odgers; Sam Finlayson; Kenneth Jung; Paea LePendu; Nigam H Shah
Journal: Drug Saf Date: 2014-10 Impact factor: 5.606

3. Do not use bisphosphonates without scientific evidence, neither in treatment nor prophylactic, in the treatment of stress fractures.

Authors: Ingrid Ekenman
Journal: Knee Surg Sports Traumatol Arthrosc Date: 2009-05 Impact factor: 4.342

4. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.

Alendronate and risedronate: reports of severe bone, joint, and muscle pain.

1. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.

2. Text mining for adverse drug events: the promise, challenges, and state of the art.

3. Do not use bisphosphonates without scientific evidence, neither in treatment nor prophylactic, in the treatment of stress fractures.

4. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.

5. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.

6. Bisphosphonates for the treatment of osteoporosis: insights for clinicians.

7. Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect.

8. Diffuse skeletal pain after administration of alendronate.

Review 9. Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.

10. Profound muscle weakness and pain after one dose of actonel.